Silo rises on deal to jointly develop ketamine-based implant to manage pain

Silo Pharma

29/11/2024 13:37

** Drug developer Silo Pharma's  SILO.O  shares rise 12.2%
to $1.01 premarket
    ** Co says it has entered into a joint development agreement
with privately-held Kymanox for SP-26, a ketamine-based implant
device for fibromyalgia and chronic pain
    ** Kymanox will conduct an initial proof-of-concept design
phase followed by full system prototype and feasibility testing
to determine optimal insertion depth in tissue
    ** Kymanox is also SILO's regulatory partner for SPC-15, a
targeted treatment for stress-induced affective disorders
including PTSD
    ** Up to last close, SILO down 37.5% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))